Brief: Organicell Regenerative Medicine - FDA Granted Emergency, Expanded Access Approval To Treat 2 Mild To Moderate Covid-19 Patients

Zeo Scientifix

02/09/2020 12:06

Sept 2 (Reuters) - Organicell Regenerative Medicine Inc
 BPSR.PK :
    * ORGANICELL REGENERATIVE MEDICINE - FDA GRANTED EMERGENCY,
EXPANDED ACCESS APPROVAL TO TREAT 2 MILD TO MODERATE COVID-19
PATIENTS
    * ORGANICELL REGENERATIVE MEDICINE - FDA GRANTED EMERGENCY,
EXPANDED ACCESS APPROVAL TO TREAT 1 "LONG HAULER" POST COVID-19
PATIENT
    * ORGANICELL REGENERATIVE MEDICINE - 6 OUTPATIENTS WITH
DIFFERENT
STAGES OF COVID-19 WERE TREATED WITH ZOFIN REPORTING SIGNIFICANT
IMPROVEMENT
    * ORGANICELL REGENERATIVE MEDICINE - WILL CONSIDER EXPANDING
ZOFIN
MANUFACTURING CAPABILITY, IF POSITIVE PATIENT RESULTS CONTINUE
    * ORGANICELL - TO COMMENCE PATIENT ENROLLMENT THIS WEEK IN
PHASE
I/II CLINICAL TRIAL TO EVALUATE TREATMENT OF ZOFIN IN MODERATE
TO SEVERE COVID-19 PATIENTS

Source text for Eikon:  ID:nBw9zpRLqa 
Further company coverage:  BPSR.PK 

 ((Reuters.Briefs@thomsonreuters.com;))